Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Read the full news release HERE

Capricor Therapeutics, which received early funding from CureDuchenne, has announced positive 3-year results from the HOPE-2 open-label extension study.  Individuals receiving CAP-1002 continue to show upper-limb and cardiac benefits after 3 years of treatment, compared to an external control group of similar DMD patients.  Results from the pivotal Phase 3 HOPE-3 trial are expected in the fourth quarter of 2024. 

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.